Follow
Manu Vanaerschot
Manu Vanaerschot
Roche Diagnostics, Infectious Diseases
Verified email at roche.com
Title
Cited by
Cited by
Year
Whole genome sequencing of multiple Leishmania donovani clinical isolates provides insights into population structure and mechanisms of drug resistance
T Downing, H Imamura, S Decuypere, TG Clark, GH Coombs, JA Cotton, ...
Genome research 21 (12), 2143-2156, 2011
4822011
Increasing failure of miltefosine in the treatment of Kala-azar in Nepal and the potential role of parasite drug resistance, reinfection, or noncompliance
S Rijal, B Ostyn, S Uranw, K Rai, NR Bhattarai, TPC Dorlo, JH Beijnen, ...
Clinical Infectious Diseases 56 (11), 1530-1538, 2013
3532013
Mapping the malaria parasite druggable genome by using in vitro evolution and chemogenomics
AN Cowell, ES Istvan, AK Lukens, MG Gomez-Lorenzo, M Vanaerschot, ...
Science 359 (6372), 191-199, 2018
2162018
Evolutionary genomics of epidemic visceral leishmaniasis in the Indian subcontinent
H Imamura, T Downing, F Van den Broeck, MJ Sanders, S Rijal, S Sundar, ...
Elife 5, e12613, 2016
1602016
Modulation of Aneuploidy in Leishmania donovani during Adaptation to Different In Vitro and In Vivo Environments and Its Impact on Gene Expression
F Dumetz, H Imamura, M Sanders, V Seblova, J Myskova, P Pescher, ...
MBio 8 (3), 10.1128/mbio. 00599-17, 2017
1492017
Evaluation of normalization methods to pave the way towards large-scale LC-MS-based metabolomics profiling experiments
BA Ejigu, D Valkenborg, G Baggerman, M Vanaerschot, E Witters, ...
Omics: a journal of integrative biology 17 (9), 473-485, 2013
1212013
Open-source discovery of chemical leads for next-generation chemoprotective antimalarials
Y Antonova-Koch, S Meister, M Abraham, MR Luth, S Ottilie, AK Lukens, ...
Science 362 (6419), eaat9446, 2018
1102018
Molecular Mechanisms of Drug Resistance in Natural Leishmania Populations Vary with Genetic Background
S Decuypere, M Vanaerschot, K Brunker, H Imamura, S Müller, B Khanal, ...
PLoS neglected tropical diseases 6 (2), e1514, 2012
1002012
Treatment failure in leishmaniasis: drug-resistance or another (epi-) phenotype?
M Vanaerschot, F Dumetz, S Roy, A Ponte-Sucre, J Arevalo, JC Dujardin
Expert review of anti-infective therapy 12 (8), 937-946, 2014
862014
Antileishmanial Activity of a Series of N2,N4-Disubstituted Quinazoline-2,4-diamines
KS Van Horn, X Zhu, T Pandharkar, S Yang, B Vesely, M Vanaerschot, ...
Journal of medicinal chemistry 57 (12), 5141-5156, 2014
822014
Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain
K Rai, B Cuypers, NR Bhattarai, S Uranw, M Berg, B Ostyn, JC Dujardin, ...
MBio 4 (5), 10.1128/mbio. 00611-13, 2013
822013
Linking in vitro and in vivo survival of clinical Leishmania donovani strains
M Vanaerschot, I Maes, M Ouakad, V Adaui, L Maes, S De Doncker, ...
PLoS One 5 (8), e12211, 2010
772010
Detection of Leptomonas sp. parasites in clinical isolates of Kala-azar patients from India
P Srivastava, VK Prajapati, M Vanaerschot, G Van der Auwera, ...
Infection, Genetics and Evolution 10 (7), 1145-1150, 2010
712010
Identification of a polymorphism in the N gene of SARS-CoV-2 that adversely impacts detection by reverse transcription-PCR
M Vanaerschot, SA Mann, JT Webber, J Kamm, SM Bell, J Bell, SN Hong, ...
Journal of Clinical Microbiology 59 (1), 10.1128/jcm. 02369-20, 2020
672020
Drug resistance in vectorborne parasites: multiple actors and scenarios for an evolutionary arms race
M Vanaerschot, S Huijben, F Van den Broeck, JC Dujardin
FEMS microbiology reviews 38 (1), 41-55, 2014
642014
Combining stage specificity and metabolomic profiling to advance antimalarial drug discovery
JM Murithi, ES Owen, ES Istvan, MCS Lee, S Ottilie, K Chibale, ...
Cell chemical biology 27 (2), 158-171. e3, 2020
632020
LC-MS metabolomics from study design to data-analysis–using a versatile pathogen as a test case
M Berg, M Vanaerschot, A Jankevics, B Cuypers, R Breitling, JC Dujardin
Computational and structural biotechnology journal 4 (5), e201301002, 2013
632013
Treatment of Visceral Leishmaniasis: Model-Based Analyses on the Spread of Antimony-Resistant L. donovani in Bihar, India
A Stauch, HP Duerr, JC Dujardin, M Vanaerschot, S Sundar, M Eichner
PLoS neglected tropical diseases 6 (12), e1973, 2012
632012
Genome-wide SNP and microsatellite variation illuminate population-level epidemiology in the Leishmania donovani species complex
T Downing, O Stark, M Vanaerschot, H Imamura, M Sanders, ...
Infection, Genetics and Evolution 12 (1), 149-159, 2012
632012
UCT943, a next-generation Plasmodium falciparum PI4K inhibitor preclinical candidate for the treatment of malaria
C Brunschwig, N Lawrence, D Taylor, E Abay, M Njoroge, GS Basarab, ...
Antimicrobial agents and chemotherapy 62 (9), 10.1128/aac. 00012-18, 2018
622018
The system can't perform the operation now. Try again later.
Articles 1–20